Valuation : Prenetics Global Limited

Market Cap 429M 369M 347M 317M 593M 40.6B 595M 4.12B 1.59B 20.79B 1.61B 1.58B 66.22B P/E 2026 *
-7.59x
P/E 2027 * -21.2x
Enterprise Value 429M 369M 347M 317M 593M 40.6B 595M 4.12B 1.59B 20.79B 1.61B 1.58B 66.22B EV / Sales 2026 *
1.92x
EV / Sales 2027 * 1.07x
Free-Float
85.5%
Yield 2026 *
-
Yield 2027 * -
1 day-0.74%
1 week-1.24%
Current month-3.09%
1 month+42.44%
3 months+28.10%
6 months+42.92%
Current year+61.52%
1 week 25.01
Extreme 25.01
27.24
1 month 17.4
Extreme 17.4
27.24
Current year 14
Extreme 14
27.24
1 year 8.1
Extreme 8.1
27.24
3 years 2.85
Extreme 2.85
27.24
5 years 2.85
Extreme 2.85
131.25
10 years 2.85
Extreme 2.85
131.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 01/01/2014
Chief Executive Officer 47 01/01/2014
Director of Finance/CFO 41 01/01/2018
Director TitleAgeSince
Chairman 47 01/01/2014
Director/Board Member 38 -
Director/Board Member - 16/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/26 Exercice

Director

4,000 0.0257%
25/8/26 Buy

CFO of IM8 (US) LLC

5,100 0.0328%
24/8/26 Buy

Chief Executive Officer

17,181 0.1104%
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%-1.24%+214.46%+239.06% 429M
-0.42%-3.68%-18.51%+6.67% 187B
+1.15%+3.22%+1.37%+16.68% 120B
-1.86%+2.77%+13.15%+89.47% 63.15B
+0.02%-1.07%+17.69%+45.19% 51.75B
-1.54%-2.52%-3.98%-30.72% 50.32B
-2.02%-3.22%+9.18%-17.76% 33.17B
0.00%+3.71% - - 32.1B
-0.81%+0.74%+35.59%-16.03% 23.93B
-2.41%-6.52%-10.28%+8.53% 22.99B
Average -0.86%-0.55%+28.74%+37.90% 58.57B
Weighted average by Cap. -0.47%-0.64%-1.35%+16.31%

Financials

2026 *2027 *
Net sales 224M 192M 181M 165M 309M 21.16B 310M 2.15B 829M 10.83B 840M 822M 34.51B 400M 344M 324M 295M 553M 37.84B 554M 3.84B 1.48B 19.38B 1.5B 1.47B 61.73B
Net income -64.13M -55.15M -51.87M -47.35M -88.56M -6.07B -88.85M -615M -238M -3.11B -241M -236M -9.89B -21.51M -18.5M -17.4M -15.88M -29.7M -2.03B -29.8M -206M -79.73M -1.04B -80.77M -79.01M -3.32B
Net Debt - -
Logo Prenetics Global Limited
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Employees
98
Date Price Change Volume
04/09/26 US$25.44 -0.74% 105,973
03/09/26 US$25.63 -1.61% 203,495
02/09/26 US$26.05 +0.93% 336,490
01/09/26 US$25.81 -1.68% 181,542
31/08/26 US$26.25 +1.90% 196,919
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
25.44USD
Average target price
35.17USD
Spread / Average Target
+38.23%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!